First approvals for Amgen's Prolia
This article was originally published in Scrip
Executive Summary
Amgen's RANK ligand targeting antibody Prolia (denosumab) has been approved in its first market, the EU. Roll out of the product will begin with a launch in the UK next week, where it will cost £183 per injection (one injection is needed every six months); other early markets are expected to be Germany and the Nordic countries.